A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients

被引:25
|
作者
Szkandera, Joanna [1 ,2 ]
Pichler, Martin [1 ]
Absenger, Gudrun [1 ,2 ]
Stotz, Michael [1 ]
Weissmueller, Melanie [1 ]
Samonigg, Hellmut [1 ]
Asslaber, Martin [3 ]
Lax, Sigurd [5 ]
Leitner, Gerhard [6 ]
Winder, Thomas [7 ]
Renner, Wilfried [4 ]
Gerger, Armin [1 ,2 ]
机构
[1] Med Univ Graz, Dept Med, Div Clin Oncol, A-8036 Graz, Austria
[2] Med Univ Graz, Div Clin Oncol, Res Unit Genet Epidemiol & Pharmacogenet, A-8036 Graz, Austria
[3] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria
[4] Med Univ Graz, Clin Inst Med & Lab Diagnost, A-8036 Graz, Austria
[5] Gen Hosp Graz West, Dept Pathol, Graz, Austria
[6] Gen Hosp Leoben, Dept Pathol, Leoben, Austria
[7] Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland
关键词
COLORECTAL-CANCER PATIENTS; SINGLE NUCLEOTIDE POLYMORPHISMS; FRIZZLED-RELATED PROTEIN; STEM-CELLS; GENETIC-POLYMORPHISM; TARGETING HEDGEHOG; BREAST-CANCER; TUMOR-MARKER; PATHWAY; ASSOCIATION;
D O I
10.1158/1078-0432.CCR-13-1517
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cumulating evidence indicates that germline variants in the Wnt, Notch, and Hedgehog pathways are involved in colon carcinoma progression and metastasis. We investigated germline polymorphisms in a comprehensive panel of Wnt, Notch, and Hedgehog pathway genes to predict time to recurrence (TTR) and overall survival in patients with stage II and III colon carcinoma. Experimental Design: A total of 742 consecutively collected patients with stage II and III colon carcinoma were included in this retrospective study. Genomic DNA was analyzed for 18 germline polymorphisms in Wnt, Notch, and Hedgehog pathway genes (SFRP, DKK 2 and 3, AXIN2, APC, MYC, TCF7L2, NOTCH2, and GLI1) by TaqMan 5'-exonuclease assays. Results: In univariate analysis, the homozygous mutant variant of GLI1 rs2228226G>C was significantly associated with decreased TTR in a recessive genetic model after adjustment for multiple testing [HR = 2.35; confidence interval (95% CI), 1.48-3.74; P < 0.001] and remained significant in multivariate analysis including clinical stage, lymphovascular-, vascular-, and perineural-invasion (HR 2.43; CI 95%, 1.52-3.87; P < 0.001). In subanalyses, the association was limited to patients with surgery alone (HR = 3.21; CI 95%, 1.59-6.49; P = 0.001), in contrast with patients with adjuvant chemotherapy (HR 0.82; CI 95%, 0.35-1.95; P = 0.657). When the subgroup of patients with " high-risk" GLI1 rs2228226 C/C genotype was analyzed, no benefit of adjuvant 5-fluorouracil-based chemotherapy could be found. Conclusion: This is the first study identifying GLI1 rs2228226G>C as an independent prognostic marker in patients with stage II and III colon carcinoma. Prospective studies are warranted to validate our findings.
引用
收藏
页码:1687 / 1697
页数:11
相关论文
共 50 条
  • [41] Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey
    Vahide I. Ugur
    Sakire P. Kara
    Bulent Kucukplakci
    Taciser Demirkasimoglu
    Cem Misirlioglu
    Aytul Ozgen
    Yesim Elgin
    Ergun Sanri
    Kadri Altundag
    Nadi Ozdamar
    Medical Oncology, 2008, 25 : 63 - 68
  • [42] Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients
    Shinto, Eiji
    Oki, Eiji
    Shimokawa, Mototsugu
    Yamaguchi, Shigeki
    Ishiguro, Megumi
    Hasegawa, Seiji
    Takii, Yasumasa
    Ishida, Hideyuki
    Kusumoto, Tetsuya
    Morita, Masaru
    Tomita, Naohiro
    Shiozawa, Manabu
    Tanaka, Masafumi
    Ozawa, Heita
    Hashiguchi, Yojiro
    Ohnuma, Shinobu
    Tada, Sachiyo
    Matsushima, Tomoko
    Yamagishi, Keisuke
    Hase, Kazuo
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (08) : 5239 - 5247
  • [43] Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients
    Eiji Shinto
    Eiji Oki
    Mototsugu Shimokawa
    Shigeki Yamaguchi
    Megumi Ishiguro
    Seiji Hasegawa
    Yasumasa Takii
    Hideyuki Ishida
    Tetsuya Kusumoto
    Masaru Morita
    Naohiro Tomita
    Manabu Shiozawa
    Masafumi Tanaka
    Heita Ozawa
    Yojiro Hashiguchi
    Shinobu Ohnuma
    Sachiyo Tada
    Tomoko Matsushima
    Keisuke Yamagishi
    Kazuo Hase
    Annals of Surgical Oncology, 2023, 30 : 5239 - 5247
  • [44] Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis
    Rosati, G.
    Galli, F.
    Cantore, M.
    Lonardi, S.
    Banzi, M.
    Zampino, M. G.
    Mattioli, R.
    Pella, N.
    Ronzoni, M.
    Di Bartolomeo, M.
    Tamberi, S.
    Marchetti, P.
    Bozzarelli, S.
    Corsi, D. C.
    Bochicchio, A. M.
    Artioli, F.
    Labianca, R.
    Galli, F.
    Bilancia, D.
    Bregni, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon
    Li, Jing
    Gupta, Manish
    Jin, Denise
    Xin, Yan
    Visich, Jennifer
    Allison, David E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 575 - 580
  • [46] Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon
    Jing Li
    Manish Gupta
    Denise Jin
    Yan Xin
    Jennifer Visich
    David E. Allison
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 575 - 580
  • [47] B-RAF V600E MUTATION IS A PROGNOSTIC FACTOR IN STAGE II AND III COLON CARCINOMA PATIENTS
    Farina, A.
    Moerland, E.
    Van Lijnschoten, G.
    Creemers, G. J.
    Lemmens, V. E. P. P.
    Rutten, H. J. T.
    Van den Brule, A. J. C.
    ANNALS OF ONCOLOGY, 2010, 21 : I17 - I18
  • [48] Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients
    Lanza, Giovanni
    Gafa, Roberta
    Santini, Alessandra
    Maestri, Iva
    Guerzoni, Laura
    Cavazzini, Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2359 - 2367
  • [49] Genomic classifiers (ColoPrint/MSI-Print) predict outcome and chemotherapy benefit in stage II and III colon cancer patients.
    Kopetz, Scott
    Jiang, Zhi-Qin
    Overman, Michael J.
    Dreezen, Christa
    Tian, Sun
    Li, Ying
    Simon, Iris
    Chang, George J.
    Maru, Dipen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [50] PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study
    Puccini, A.
    Ferrando, L.
    Mazzarella, L.
    Frige, G.
    Pessino, A.
    Pastorino, A.
    Martelli, V.
    Garuti, A.
    Ballestrero, A.
    Torri, V.
    Labianca, R.
    Fassan, M.
    Lonardi, S.
    Zoppoli, G.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S13 - S13